文献速递免疫规划

初始加强剂次Vero细胞培养灭活日本脑炎疫苗(JE-VC)的长期免疫原性及第二剂JE-VC加强在既往接种小鼠脑源灭活日本脑炎疫苗儿童中的安全性与免疫原性

Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
PubMed 文献 · Vaccine · 2018-01-01

本研究为多中心、开放标签临床试验,纳入6岁健康韩国儿童,评估2岁时接种第1剂加强JE-VC或JE-MB后的长期免疫原性,以及6岁时第2剂JE-VC加强的安全性和免疫原性。结果显示第1剂加强后约4年JE-VC组血清保护率100%、GMT 1113.8,JE-MB组分别为88.5%、56.3;第2剂JE-VC加强后所有受试者均达血清保护,JE-VC组GMT 8144.1高于JE-MB组942.5(p < 0.001),未报告严重疫苗相关不良事件。

要点

  • 第1剂加强JE-VC后约4年血清保护率100%、GMT 1113.8
  • 既往JE-MB基础及第1剂加强者血清保护率88.5%、GMT 56.3
  • 第2剂JE-VC加强后所有受试者均血清保护,JE-VC组GMT高于JE-MB组

核心结论

  • 第1剂JE-VC和JE-MB加强均显示至少4年的长期免疫原性,第2剂JE-VC加强在既往接种JE-VC或JE-MB的儿童中显示良好的安全性和免疫原性。

研究设计与样本

  • 多中心、开放标签临床试验,研究对象为参加既往JE疫苗试验的健康韩国6岁儿童,所有受试者皮下接种1剂Boryung Cell Culture Japanese Encephalitis Vaccine®(JE-VC)作为加强免疫。

主要发现

  • 第1剂JE-VC加强后约4年,中和抗体血清保护率为100%、几何平均滴度(GMT)为1113.8。
  • 既往接种JE-MB并接受第1剂加强者,血清保护率为88.5%、GMT为56.3。
  • 第2剂JE-VC加强后,所有既往接种JE-MB或JE-VC并接受第1剂加强的受试者均对JE病毒血清保护。
  • 接种后JE-VC组中和抗体GMT为8144.1,高于JE-MB组的942.5(p < 0.001)。
  • 第2剂JE-VC加强显示良好安全性,未报告严重疫苗相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. METHOD: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC). RESULT: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. CONCLUSION: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. ClinicalTtrials.gov Identifier: NCT02532569.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yun KW, Lee HJ, Park JY, et al. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. Vaccine. 2018. PMID: 29429815. doi:10.1016/j.vaccine.2018.01.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。